A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 19271 participants.
Also called NCT01991795
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 19,271 participants
- Sponsor
- Registry
-
NCT01991795
-
- Other papers using this trial's data
- Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Puerto Rico, Romania, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01991795. Randomized; quadruple masking; primary purpose prevention. Start 2014-02-10 (actual); primary completion 2019-01-25 (actual). Results posted on 2020-03-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
- Acronym
- THEMIS
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Ticagrelor 60 mg
- Intervention (Drug)
- Ticagrelor placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01991795- Content hash
e4f0fe4157a45848550bd044a9a0ae8d96868fccf589d0f893b85f897e07e8a2